BOTHELL, Wash., March 9 /PRNewswire-FirstCall/ -- Helix BioMedix
(OTC Bulletin Board: HXBM.OB), a developer of bioactive peptides, today
announced that Timothy Falla, Ph.D., Chief Scientific Officer, is scheduled to
present an overview of the company at Invest Northwest on March 21, 2006 at
the Bell Harbor Conference Center, Seattle, Washington. Helix BioMedix's
presentation at Invest Northwest is scheduled for 11:55 am Pacific Time
(2:55 pm Eastern Time).
Now in its fifth year, Invest Northwest is a forum for senior executives
from Northwest public and private life science companies to tell their stories
to institutional investors, analysts, investment bankers, fund managers,
venture capitalists, angel investors and prospective corporate partners.
Invest Northwest is produced by the Washington Biotechnology & Biomedical
Association in collaboration with BC Biotech, BC Medtech, BioAlberta,
BioIdaho, Montana BioScience Alliance and the Oregon Bioscience Association.
About Helix BioMedix
Helix BioMedix, Inc. is a late stage biopharmaceutical company that has a
portfolio of issued patents that covers six distinct classes of peptides,
including over 100,000 unique peptide sequences. The company's mission is to
become the industry leader in developing and commercializing small proteins
known as bioactive peptides. The antimicrobial and wound healing properties of
these peptides qualify them for inclusion in a wide range of both
pharmaceutical and consumer products. The company is currently focused on the
development of selected peptides as topical anti-infectives and in wound
healing. Non-pharmaceutical applications being pursued by Helix BioMedix
include adjuvants for cosmetics/cosmeceuticals, personal care, plant health,
animal health and wide-spectrum biocides. More information about the company
and its proprietary peptides can be found on the company's website at
http://www.helixbiomedix.com.
Contact: Investor Relations:
Helix BioMedix, Inc. Cameron Associates
David H. Kirske, 425-402-8400 Alison Ziegler, 212-554-5469
dkirske@helixbiomedix.com alison@cameronassoc.com
or:
SOURCE Helix BioMedix, Inc.
 back to top
Related links:
http://www.helixbiomedix.com
CONTACT:
David H. Kirske of Helix BioMedix, Inc.,
+1-425-402-8400, or dkirske@helixbiomedix.com; or investors,
Alison Ziegler of Cameron Associates, +1-212-554-5469, or
alison@cameronassoc.com, for Helix BioMedix, Inc.
|
